GO Therapeutics is exploiting unique aspects of cancer cell biology to develop a new class of cancer therapies for previously intractable solid tumors.
We target O-linked glycoproteins specific to cancer cells to develop proprietary, high-affinity antibodies to novel cancer-specific targets. Our antibodies are the basis for a broad array of potent cancer-killing modalities including T-cell bispecifics (TCBs), CAR-T, and antibody drug conjugates (ADCs). Each are designed to kill cancer while sparing healthy tissue.
Company Details
- Employees
- 9
- Founded
- 2014
- Address
- 22 Strathmore, Natick,massachusetts 01760,united States
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- gotherapeutics.com
- Keywords
- Drug development, Antigen development, Antobody developement, O-glycosylation, Glycoproteomics, Glycopeptides, Cellular engineering.
- HQ
- Natick, Massachusetts
Go Therapeutics Questions
Go Therapeutics's website is gotherapeutics.com
Go Therapeutics's LinkedIn profile is https://www.linkedin.com/company/go-therapeutics
Go Therapeutics has
9 employees.
View email and phone details for 9
employees at Go Therapeutics.
Go Therapeutics's industry is
Biotechnology Research
Go Therapeutics's top competitors are
Tallac Therapeutics,
Metrowest Life Sciences Network,
Tessera Therapeutics,
General Oncology,
Abi-Lab,
Alx Oncology,
Affyimmune Therapeutics,
Cugene Inc.,
Minerva Biotechnologies,
Mercy Bioanalytics, Inc..
Go Therapeutics's support email address is info@gotherapeutics.com
Go Therapeutics's categories are Biotechnology Research
Go Therapeutics's founding year is 2014
